Erasca announced the closing of an upsized public offering that sold 25,875,000 shares at $10.00 each, including full exercise of the underwriters’ option. The company reported gross proceeds of approximately $258.8 million before fees and expenses. Erasca said all shares were sold by the company and that funds will support development of its precision oncology programs targeting RAS/MAPK pathway-driven cancers.